EVMN
Evommune, Inc.NYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.01B
P/E Ratio
—
EPS
$-11.22
Beta
—
52W High
$33.20
52W Low
$13.88
50-Day MA
$25.36
200-Day MA
$21.72
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Evommune, Inc.
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for the treatment of immunological disorders. With a robust pipeline designed to tackle significant unmet medical needs, Evommune leverages advanced research and technology to enhance immune response and patient outcomes. The company's dedication to scientific rigor and strategic partnerships supports its ambition to become a leader in the rapidly evolving field of immunotherapy. As Evommune progresses through clinical trials, it aims to deliver transformative solutions that could redefine care standards in immunology and provide renewed hope for patients.
Fundamentals
| Revenue (TTM) | $13.00M |
| Gross Profit (TTM) | $13.00M |
| EBITDA | $-79.68M |
| Operating Margin | -624.00% |
| Return on Equity | -54.40% |
| Return on Assets | -33.70% |
| Revenue/Share (TTM) | $2.12 |
| Book Value | $6.52 |
| Price-to-Book | 4.90 |
| Price-to-Sales (TTM) | 77.49 |
| EV/Revenue | 66.15 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $36.02M |
| Float | $19.60M |
| % Insiders | 7.98% |
| % Institutions | 91.73% |
Analyst Ratings
Consensus ($51.57 target)
2
Strong Buy7
BuyData last updated: 4/21/2026